Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

MESALAMINE ER 500 MG CAPSULE

Mesalamine
$3.4704per EA

Strength

500 mg/1

Manufacturer

Sun Pharmaceutical Industries Inc.

NDC

63304008913

Classification

Generic

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Last Updated

6/18/2025

Active Ingredients

MESALAMINE

Approval Type

Generic (ANDA)

FDA Application

ANDA214585

On Market Since

5/13/2022

Pharmacological Classes

Aminosalicylate
Aminosalicylic Acids

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

-2.6%

3Y

-23.9%

5Y

N/A

All

-21.1%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

SULFASALAZINE 500 MG TABLET
Generic
00093323401•Teva Pharmaceuticals USA Inc.
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
00093323405•Teva Pharmaceuticals USA Inc.
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
00093323410•Teva Pharmaceuticals USA Inc.
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
11534020001•Sunrise Pharmaceutical Inc.
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
11534020004•Sunrise Pharmaceutical Inc.
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
59762500005•Mylan Pharmaceuticals Inc.
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
59762500006•Mylan Pharmaceuticals Inc.
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
62135096001•Chartwell RX LLC
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
62135096005•Chartwell RX LLC
$0.1971
per EA
SULFASALAZINE 500 MG TABLET
Generic
62135096010•Chartwell RX LLC
$0.1971
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy